한글목차

핵의학 방사성 동위원소 시장 규모는 최근 현저한 성장을 이루고 있습니다. 2025년 88억 5,000만 달러에서 2026년에는 95억 8,000만 달러에 이르고, CAGR 8.2%로 성장할 전망입니다. 지난 몇 년간의 성장은 진단 영상에 테크네튬 99m이 광범위하게 사용되고, 핵의학 심장 검사의 보급 확대, 암 및 갑상선 질환의 발병률 증가, 병원 내 핵의학 부서의 확장, 방사성 동위원소 치료의 초기 임상적 성공에 기인하는 것으로 보입니다.

핵의학 방사성 동위원소 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 127억 5,000만 달러에 이르고, CAGR은 7.4%를 나타낼 전망입니다. 예측 기간의 성장 요인으로는 맞춤형 암 치료 수요 증가, 루테튬177 및 악티늄225 치료법 이용 확대, PET 영상진단 인프라 확충, 사이클로트론 및 원자로 시설에 대한 투자 증가, 신흥국의 핵의학 도입 진전 등을 꼽을 수 있습니다. 예측 기간 동안 주요 동향으로는 종양학 치료에서 테라노스틱스 도입 증가, PET 및 SPECT 영상진단 프로세스 수요 증가, 표적형 알파 및 베타선 방출체 사용 증가, 심장학 및 신경학 분야에서의 핵의학 확대, 국내 방사성 동위원소 생산에 대한 집중 강화 등이 있습니다. 등을 들 수 있습니다.

향후 몇 년 동안 심혈관 질환의 발생률 증가가 핵의학용 방사성 동위원소 시장의 성장을 견인할 것으로 예측됩니다. 심혈관 질환이란 심장과 혈관에 영향을 미치는 다양한 병태를 말합니다. 심혈관 질환 증가는 좌식 생활, 부적절한 식습관, 비만율 증가, 고령화 사회와 관련이 있습니다. 핵의학용 방사성 동위원소는 심장 기능, 혈류, 조직의 생존 상태에 대한 상세한 정보를 제공함으로써 심혈관 질환의 진단, 평가, 관리에 필수적이며, 정확한 진단과 효과적인 치료 계획 수립에 매우 중요합니다. 예를 들어, 2024년 1월 미국 비영리단체인 미국심장협회가 발표한 자료에 따르면, 2024년 심혈관 질환으로 인한 연령 조정 사망률은 2024년 10만 명당 233.3명으로 2023년 224.4명에서 4.0% 증가했다고 합니다. 그 결과, 심혈관 질환의 유병률 증가가 핵의학용 방사성 동위원소 시장의 성장을 가속하고 있습니다.

핵의학용 방사성 동위원소 시장의 주요 기업들은 정밀 영상 진단 및 표적 치료를 강화하기 위해 차세대 세라믹 방사성의약품과 같은 첨단 솔루션 개발에 주력하고 있습니다. 차세대 방사성의약품은 체내의 특정 세포를 정밀하게 표적화하여 질병의 발견과 정확한 치료를 동시에 할 수 있는 고도로 전문화된 방사성의약품입니다. 예를 들어, 2025년 11월, 미국 캘리포니아 대학교는 핵의학을 광범위한 방사선 의학 부서의 일부로 유지하는 것이 아니라 완전히 독립된 '핵의학 및 세라믹 학과'를 신설했습니다. 이 신설된 학과에서는 첨단 이미징 기술과 표적형 방사성의약품 치료의 활용을 가속화하는 것을 목표로 하고 있습니다. 또한, 정밀의료를 촉진하고 세라믹 치료의 혁신을 촉진하기 위해 연구, 교육, 임상 프로그램을 강화하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업 및 혁신 기업

제38장 세계 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병(M&A)

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Nuclear medicine radioisotopes are radioactive isotopes used in nuclear medicine to diagnose, treat, and investigate various medical conditions. These isotopes emit radiation that can be detected and imaged with specialized equipment or can provide therapeutic doses of radiation to targeted tissues. Nuclear medicine radioisotopes are essential in modern medical diagnostics and treatments, providing critical information and therapeutic options that improve patient outcomes.

The main types of nuclear medicine radioisotopes include technetium-99m (Tc-99m), thallium-201 (Tl-201), iodine (I-123), fluorine-18, rubidium-82 (Rb-82), iodine-131 (I-131), lutetium-177 (Lu-177), radium-223 (Ra-223) and alpharadin, actinium-225 (Ac-225), among others. Technetium-99m (Tc-99m) is a radioactive isotope widely utilized in nuclear medicine imaging procedures for the diagnosis of various medical conditions. Its uses cover areas such as oncology, cardiology, thyroid, neurology, and more, serving end users including hospitals, diagnostic centers, specialty clinics, education and research institutes, and others.

Tariffs have impacted the nuclear medicine radioisotopes market by increasing costs associated with importing radioisotopes, enriched materials, cyclotron components, and shielding equipment. These effects are most pronounced in regions dependent on cross-border isotope supply chains, including North America and parts of Europe. Supply disruptions and higher logistics costs have affected diagnostic and therapeutic segments, particularly short half-life isotopes. However, tariffs have also encouraged domestic isotope production, regional cyclotron investments, and supply chain localization, supporting long-term market resilience.

The nuclear medicine radioisotopes market research report is one of a series of new reports from The Business Research Company that provides nuclear medicine radioisotopes market statistics, including nuclear medicine radioisotopes industry global market size, regional shares, competitors with a nuclear medicine radioisotopes market share, detailed nuclear medicine radioisotopes market segments, market trends and opportunities, and any further data you may need to thrive in the nuclear medicine radioisotopes industry. This nuclear medicine radioisotopes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The nuclear medicine radioisotopes market size has grown strongly in recent years. It will grow from $8.85 billion in 2025 to $9.58 billion in 2026 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to widespread use of technetium-99m in diagnostic imaging, growing adoption of nuclear cardiology procedures, increasing prevalence of cancer and thyroid disorders, expansion of hospital-based nuclear medicine departments, early clinical success of radioisotope-based therapies.

The nuclear medicine radioisotopes market size is expected to see strong growth in the next few years. It will grow to $12.75 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to rising demand for personalized cancer treatment, increasing use of lutetium-177 and actinium-225 therapies, expansion of PET imaging infrastructure, growing investments in cyclotron and reactor facilities, rising adoption of nuclear medicine in emerging economies. Major trends in the forecast period include rising adoption of theranostics in oncology care, growing demand for PET and SPECT imaging procedures, increased use of targeted alpha and beta emitters, expansion of nuclear medicine in cardiology and neurology, strengthening focus on domestic radioisotope production.

The rising incidence of cardiovascular diseases is expected to drive the expansion of the nuclear medicine radioisotope market in the coming years. Cardiovascular diseases include a variety of conditions that affect the heart and blood vessels. The increase in cardiovascular disease cases is linked to sedentary lifestyles, poor dietary habits, higher obesity rates, and aging populations. Nuclear medicine radioisotopes are essential for diagnosing, evaluating, and managing cardiovascular diseases by offering detailed information on cardiac function, perfusion, and tissue viability, which are vital for accurate diagnosis and effective treatment planning. For instance, in January 2024, the American Heart Association, a US-based non-profit organization, reported that the age-adjusted death rate from cardiovascular disease increased to 233.3 per 100,000 in 2024, up 4.0% from 224.4 per 100,000 in 2023. As a result, the increasing prevalence of cardiovascular diseases is driving the growth of the nuclear medicine radioisotope market.

Major companies in the nuclear medicine radioisotopes market are focusing on developing advanced solutions such as next-generation theranostic radiopharmaceuticals to enhance precision imaging and targeted therapies. Next-generation theranostic radiopharmaceuticals are highly specialized radioactive agents designed to both detect and accurately treat diseases by precisely targeting specific cells within the body. For instance, in November 2025, the University of California, a US-based research university, created a completely independent Department of Nuclear Medicine & Theranostics, rather than maintaining nuclear medicine as part of a broader radiology division. This newly established department aims to accelerate the use of advanced imaging and targeted radiopharmaceutical therapies. It also strengthens research, education, and clinical programs to advance precision medicine and encourage innovations in theranostic treatments.

In April 2024, Telix Pharmaceuticals Limited, an Australia-based biotechnology company, acquired ARTMS for an undisclosed amount. Through this acquisition, Telix Pharmaceuticals aimed to strengthen its nuclear medicine capabilities, optimize production processes, and broaden its range of diagnostic and therapeutic radiopharmaceuticals. ARTMS, headquartered in Canada, provides advanced radioisotope technology and operates in the field of nuclear medicine radioisotopes.

Major companies operating in the nuclear medicine radioisotopes market are Cardinal Health Inc., Bayer AG, Siemens Healthineers AG, GE HealthCare Technologies, BWX Technologies Inc., Mallinckrodt Pharmaceuticals, Bracco Imaging S.p.A., Lantheus Holdings Inc., Curium Pharma, Australian Nuclear Science and Technology Organisation (ANSTO) Health, Eckert & Ziegler Strahlen, NorthStar Medical Radioisotopes, NTP Radioisotopes, Shine Medical Technologies Inc., Jubilant DraxImage Inc., Isotopia Molecular Imaging Ltd., EczacIbasI-Monrol Nuclear Products, International Isotopes Inc., Polatom Sp. z o.o., Radiomedix Inc., Positron Corporation

North America was the largest region in the nuclear medicine radioisotopes market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nuclear medicine radioisotopes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the nuclear medicine radioisotopes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The nuclear medicine radioisotopes market consists of sales of yttrium-90, indium-111, carbon-11, samarium-153, and strontium-89. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Nuclear Medicine Radioisotopes Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses nuclear medicine radioisotopes market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for nuclear medicine radioisotopes ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The nuclear medicine radioisotopes market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Technetium-99m (Tc-99m); Thallium-201 (Tl-201); Iodine (I-123); Fluorine-18; Rubidium-82 (Rb-82); Iodine-131 (I-131); Lutetium-177 (Lu-177); Radium-223 (Ra-223) And Alpharadin; Other Types
• 2) By Application: Oncology; Cardiology; Thyroid; Neurology; Other Applications
• 3) By End-User: Hospitals; Diagnostic Centers; Specialty Clinics; Education And Research Institutes; Other End-Users
• Subsegments:
• 1) By Technetium-99m (Tc-99m): Sodium Pertechnetate Tc-99m; Tc-99m MDP (Methylene Diphosphonate); Tc-99m HMPAO (Hexamethylpropyleneamine oxime)
• 2) By Thallium-201 (Tl-201): Thallous Chloride Tl-201; Thallium-201 for Cardiac Imaging
• 3) By Iodine-123 (I-123): Iodine-123 Sodium Iodide; Iodine-123 Ioflupane (DaTscan)
• 4) By Fluorine-18: FDG (Fluorodeoxyglucose) F-18; Fluoride-18 For Bone Imaging
• 5) By Rubidium-82 (Rb-82): Rb-82 For PET (Positron Emission Tomography) Imaging; Rb-82 For Cardiac Imaging
• 6) By Iodine-131 (I-131): I-131 Sodium Iodide; I-131 For Thyroid Cancer Treatment; I-131 For Hyperthyroidism Treatment
• 7) By Lutetium-177 (Lu-177): Lu-177-DOTATATE; Lu-177 For Prostate Cancer Treatment
• 8) By Radium-223 (Ra-223): Ra-223 Dichloride (Xofigo); Alpharadin For Bone Metastasis Treatment
• 9) By Alpharadin (Radium-223 Alpha Emitters): Ac-225 For Targeted Alpha Therapy (TAT); Ac-225 For Cancer Treatment; Gallium-68 (Ga-68); Copper-64 (Cu-64); Yttrium-90 (Y-90)
• 10) By Other Types: Ac-225 For Targeted Alpha Therapy (TAT); Ac-225 For Cancer Treatment; Gallium-68 (Ga-68); Copper-64 (Cu-64); Yttrium-90 (Y-90)
• Companies Mentioned: Cardinal Health Inc.; Bayer AG; Siemens Healthineers AG; GE HealthCare Technologies; BWX Technologies Inc.; Mallinckrodt Pharmaceuticals; Bracco Imaging S.p.A.; Lantheus Holdings Inc.; Curium Pharma; Australian Nuclear Science and Technology Organisation (ANSTO) Health; Eckert & Ziegler Strahlen; NorthStar Medical Radioisotopes; NTP Radioisotopes; Shine Medical Technologies Inc.; Jubilant DraxImage Inc.; Isotopia Molecular Imaging Ltd.; EczacIbasI-Monrol Nuclear Products; International Isotopes Inc.; Polatom Sp. z o.o.; Radiomedix Inc.; Positron Corporation
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Nuclear Medicine Radioisotopes Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Nuclear Medicine Radioisotopes Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Nuclear Medicine Radioisotopes Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Nuclear Medicine Radioisotopes Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Industry 4.0 & Intelligent Manufacturing
  • 4.1.4 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Rising Adoption Of Theranostics In Oncology Care
  • 4.2.2 Growing Demand For Pet And Spect Imaging Procedures
  • 4.2.3 Increased Use Of Targeted Alpha And Beta Emitters
  • 4.2.4 Expansion Of Nuclear Medicine In Cardiology And Neurology
  • 4.2.5 Strengthening Focus On Domestic Radioisotope Production

5. Nuclear Medicine Radioisotopes Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Diagnostic Centers
• 5.3 Specialty Clinics
• 5.4 Cancer Treatment Centers
• 5.5 Education And Research Institutes

6. Nuclear Medicine Radioisotopes Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Nuclear Medicine Radioisotopes Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Nuclear Medicine Radioisotopes PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Nuclear Medicine Radioisotopes Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Nuclear Medicine Radioisotopes Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Nuclear Medicine Radioisotopes Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Nuclear Medicine Radioisotopes Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Nuclear Medicine Radioisotopes Market Segmentation

• 9.1. Global Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Iodine (I-123), Fluorine-18, Rubidium-82 (Rb-82), Iodine-131 (I-131), Lutetium-177 (Lu-177), Radium-223 (Ra-223) And Alpharadin, Other Types
• 9.2. Global Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oncology, Cardiology, Thyroid, Neurology, Other Applications
• 9.3. Global Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Diagnostic Centers, Specialty Clinics, Education And Research Institutes, Other End-Users
• 9.4. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Technetium-99m (Tc-99m), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Sodium Pertechnetate Tc-99m, Tc-99m MDP (Methylene Diphosphonate), Tc-99m HMPAO (Hexamethylpropyleneamine oxime)
• 9.5. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Thallium-201 (Tl-201), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Thallous Chloride Tl-201, Thallium-201 For Cardiac Imaging
• 9.6. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Iodine-123 (I-123), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Iodine-123 Sodium Iodide, Iodine-123 Ioflupane (DaTscan)
• 9.7. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Fluorine-18, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• FDG (Fluorodeoxyglucose) F-18, Fluoride-18 For Bone Imaging
• 9.8. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Rubidium-82 (Rb-82), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Rb-82 For PET (Positron Emission Tomography) Imaging, Rb-82 For Cardiac Imaging
• 9.9. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Iodine-131 (I-131), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• I-131 Sodium Iodide, I-131 For Thyroid Cancer Treatment, I-131 For Hyperthyroidism Treatment
• 9.10. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Lutetium-177 (Lu-177), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Lu-177-DOTATATE, Lu-177 For Prostate Cancer Treatment
• 9.11. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Radium-223 (Ra-223) And Alpharadin, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Ra-223 Dichloride (Xofigo), Alpharadin For Bone Metastasis Treatment
• 9.12. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Ac-225 For Targeted Alpha Therapy (TAT), Ac-225 For Cancer Treatment, Gallium-68 (Ga-68), Copper-64 (Cu-64), Yttrium-90 (Y-90)

10. Nuclear Medicine Radioisotopes Market Regional And Country Analysis

• 10.1. Global Nuclear Medicine Radioisotopes Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Nuclear Medicine Radioisotopes Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Nuclear Medicine Radioisotopes Market

• 11.1. Asia-Pacific Nuclear Medicine Radioisotopes Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Nuclear Medicine Radioisotopes Market

• 12.1. China Nuclear Medicine Radioisotopes Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Nuclear Medicine Radioisotopes Market

• 13.1. India Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Nuclear Medicine Radioisotopes Market

• 14.1. Japan Nuclear Medicine Radioisotopes Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Nuclear Medicine Radioisotopes Market

• 15.1. Australia Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Nuclear Medicine Radioisotopes Market

• 16.1. Indonesia Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Nuclear Medicine Radioisotopes Market

• 17.1. South Korea Nuclear Medicine Radioisotopes Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Nuclear Medicine Radioisotopes Market

• 18.1. Taiwan Nuclear Medicine Radioisotopes Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Nuclear Medicine Radioisotopes Market

• 19.1. South East Asia Nuclear Medicine Radioisotopes Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Nuclear Medicine Radioisotopes Market

• 20.1. Western Europe Nuclear Medicine Radioisotopes Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Nuclear Medicine Radioisotopes Market

• 21.1. UK Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Nuclear Medicine Radioisotopes Market

• 22.1. Germany Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Nuclear Medicine Radioisotopes Market

• 23.1. France Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Nuclear Medicine Radioisotopes Market

• 24.1. Italy Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Nuclear Medicine Radioisotopes Market

• 25.1. Spain Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Nuclear Medicine Radioisotopes Market

• 26.1. Eastern Europe Nuclear Medicine Radioisotopes Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Nuclear Medicine Radioisotopes Market

• 27.1. Russia Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Nuclear Medicine Radioisotopes Market

• 28.1. North America Nuclear Medicine Radioisotopes Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Nuclear Medicine Radioisotopes Market

• 29.1. USA Nuclear Medicine Radioisotopes Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Nuclear Medicine Radioisotopes Market

• 30.1. Canada Nuclear Medicine Radioisotopes Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Nuclear Medicine Radioisotopes Market

• 31.1. South America Nuclear Medicine Radioisotopes Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Nuclear Medicine Radioisotopes Market

• 32.1. Brazil Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Nuclear Medicine Radioisotopes Market

• 33.1. Middle East Nuclear Medicine Radioisotopes Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Nuclear Medicine Radioisotopes Market

• 34.1. Africa Nuclear Medicine Radioisotopes Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Nuclear Medicine Radioisotopes Market Regulatory and Investment Landscape

36. Nuclear Medicine Radioisotopes Market Competitive Landscape And Company Profiles

• 36.1. Nuclear Medicine Radioisotopes Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Nuclear Medicine Radioisotopes Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Nuclear Medicine Radioisotopes Market Company Profiles
  • 36.3.1. Cardinal Health Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. GE HealthCare Technologies Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. BWX Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Nuclear Medicine Radioisotopes Market Other Major And Innovative Companies

• Mallinckrodt Pharmaceuticals, Bracco Imaging S.p.A., Lantheus Holdings Inc., Curium Pharma, Australian Nuclear Science and Technology Organisation (ANSTO) Health, Eckert & Ziegler Strahlen, NorthStar Medical Radioisotopes, NTP Radioisotopes, Shine Medical Technologies Inc., Jubilant DraxImage Inc., Isotopia Molecular Imaging Ltd., EczacIbasI-Monrol Nuclear Products, International Isotopes Inc., Polatom Sp. z o.o., Radiomedix Inc.

38. Global Nuclear Medicine Radioisotopes Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Nuclear Medicine Radioisotopes Market

40. Nuclear Medicine Radioisotopes Market High Potential Countries, Segments and Strategies

• 40.1 Nuclear Medicine Radioisotopes Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Nuclear Medicine Radioisotopes Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Nuclear Medicine Radioisotopes Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer